What Eli Lilly Bulls Got Right

If you only glanced at Eli Lilly headlines in 2025, the story looked fiercely contested. Bulls pointed to aging and obesity trends, scale in GLP-1 drugs, and a higher Fair Value, while bears warned that drug pricing reforms and dependence on a few therapies could cap outcomes. Holding Eli Lilly over the past year would have returned 58.4%, including dividends. If you had faced that split view in November 2025, what exactly in the record might have justified accepting those risks?

The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.

This theme extends beyond Eli Lilly. See which of 33 healthcare AI stocks may still merit a closer look.

What Eli Lilly Investors Were Really Arguing About

The shares cost US$863 at the start of the period, and every Eli Lilly investor had to decide which story felt more believable.

The bullish narrative put fair value at US$1,190. It relied on aging and obesity trends, with an emphasis on how small molecule drugs like orforglipron and Lilly’s dose capacity build-out could support wider obesity treatment and higher net margins.

The bearish view set fair value at US$650. That camp focused on U.S. drug pricing reforms and heavy reliance on incretin therapies such as Mounjaro and Zepbound as key considerations for future earnings power.

What The Evidence Did To The Eli Lilly Debate

The biggest later datapoint for Eli Lilly was Q3 2026, when revenue reached US$24,397m and net income was US$6,451m, higher than Q3 2025. That outcome leaned toward the bullish story on demand and scale. Yet net margin slipped from 31.7% to 26.4%, which kept the bear case on pricing pressure and costs alive. Overall, the evidence cut both ways.

The useful takeaway is where to look first. When a thesis rests on premium pricing and widening profitability, track not just sales and earnings, but the net margin line over several reports to see whether operating leverage is actually turning up.

What Eli Lilly’s Price Already Bakes In

Eli Lilly now trades at US$1,411, well above where the selected Narrative’s Fair Value estimate sits, even though that Narrative highlights strong tirzepatide momentum and long patent protection.

For today’s valuation to hold, an investor has to believe GLP-1 demand and pricing power stay resilient despite cost sensitivity and future competition.

"Current production capacity is the main limiting factor, not patient willingness. Both Lilly and Novo are investing billions in new plants (for example, Lilly in Indiana, Ireland, and Germany). Analysts expect supply bottlenecks to persist through 2025 and gradually ease by 2026. This is expected to increase the number of units shipped."

One Narrative disagrees with today's price. → See where this Narrative says Eli Lilly should trade

Find Your Own Contrarian Opportunity

By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.

• Company 1 - 36% below our estimate - converts large AI infrastructure and multicloud database contracts into subscriptions.
• Company 2 - 49% below our estimate - shifts from low-margin assembly into co-designing complex hardware for regulated clients.
• Company 3 - 37% below our estimate - expands an aviation aftermarket platform through engine acquisitions and deeper OEM partnerships.

Those are three of them. See every one of the 34 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com